GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

8.51%

Market Cap

-

P/E Ratio

19.82

Dividend Yield

0.00 %

Earnings per Share

1.38 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE20.4 G0 Units
PRICE DETERMINATION TIME06/03/2026 / 09:55:53 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW20.620.2
PREV. DAY'S PRICE20.4 (06/02)
CHANGE DAY BEFORE
+0.00
0.00 %
52 WEEK HIGH / LOW31 (01/15)17.2 (07/04)
More Price Information

Key Figures (in EUR)

2027e2026e202520242023
EARNINGS PER SHARE1.490.971.381.640.89
DIVIDENDS PER SHARE0.000.000.000.000.00
DIVIDEND YIELD IN %--0.00 %0.00 %0.00 %
DIVIDEND GROWTH IN %-----
PRICE - EARNINGS RATIO15.5423.9019.8211.7832.93
PRICE - BOOK RATIO--3.252.604.44
PRICE - SALES RATIO--5.174.328.78
PRICE - CASH FLOW RATIO--16.2311.9719.60
Further Key Figures

Master Data

WKN
A1WZYB
ISIN
US3723032062
SYMBOL
GE91
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
GENMAB AS SP.ADR/1/10DK 1
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-11.30 %
-9.73 %
-19.05 %
-25.00 %
8.51 %
-43.33 %
-38.18 %
-25.55 %
HIGH23.2024.0025.4031.0031.0038.2044.4031.00
LOW20.4020.4020.4020.4017.2015.9015.9020.40
Dividend
per share
GENMAB AS SP.ADR/1/10DK 1 does not deliver dividend information

Company profile

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.